Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
evolutionRMS 1
NCT04338022Phase 3Terminated
- Sponsor
- Merck KGaA
- Start
- Jun 2020
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 31
01
Overview
Phase 3, randomised, double-blind trial of evobrutinib in multiple sclerosis (MS) (2 arms), sponsored by Merck KGaA. Primary endpoint: Annualized Relapse Rate at 172 weeks. Started Jun 2020; status: terminated.
02
Drugs
evobrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04338022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04338022.